

Strategic Partnerships to Deliver CureVac's COVID-19 Ambition

Webcast Presentation, February 5, 2021

Forward-Looking Statements




The information set forth herein does not purport to be complete or to contain all of the information you may desire. Statements contained herein are made as of the date of this document unless stated otherwise, and neither the delivery of this document at any time, nor any sale of securities, shall under any circumstances create an implication that the information contained herein is correct as of any time after such date or that information will be updated or revised to reflect information that subsequently becomes available or changes occurring after the date hereof.

This presentation of CureVac N.V. (the “company”) contains statements that constitute “forward-looking statements” as that term is defined in the United States Private Securities Litigation Reform Act of 1995, including statements that express the company’s opinions, expectations, beliefs, plans, objectives, assumptions or projections of the company regarding future events or future results, in contrast with statements that reflect historical facts. Examples include discussion of the potential efficacy of the company’s vaccine candidate and the company’s strategies, financing plans, growth opportunities and market growth. In some cases, you can identify such forward-looking statements by terminology such as “anticipate,” “intend,” “believe,” “estimate,” “plan,” “seek,” “project,” or “expect,” “may,” “will,” “would,” “could,” “potential,” “intend,” or “should,” the negative of these terms or similar expressions. Forward-looking statements are based on management’s current beliefs and assumptions and on information currently available to the company. However, these forward-looking statements are not a guarantee of the company’s performance, and you should not place undue reliance on such statements. Forward-looking statements are subject to many risks, uncertainties and other variable circumstances, including negative worldwide economic conditions and ongoing instability and volatility in the worldwide financial markets, ability to obtain funding, ability to conduct current and future preclinical studies and clinical trials, the timing, expense and uncertainty of regulatory approval, reliance on third parties and collaboration partners, ability to commercialize products, ability to manufacture any products, possible changes in current and proposed legislation, regulations and governmental policies, pressures from increasing competition and consolidation in the company’s industry, the effects of the COVID-19 pandemic on the company’s business and results of operations, ability to manage growth, reliance on key personnel, reliance on intellectual property protection, ability to provide for patient safety, and fluctuations of operating results due to the effect of exchange rates or other factors. Such risks and uncertainties may cause the statements to be inaccurate and readers are cautioned not to place undue reliance on such statements. Many of these risks are outside of the company’s control and could cause its actual results to differ materially from those it thought would occur. The forward-looking statements included in this presentation are made only as of the date hereof. The company does not undertake, and specifically declines, any obligation to update any such statements or to publicly announce the results of any revisions to any such statements to reflect future events or developments, except as required by law.

For further information, please reference the company’s reports and documents filed with the U.S. Securities and Exchange Commission (SEC). You may get these documents by visiting EDGAR on the SEC website at www.sec.gov.

Deliver on the Potential of the Curevac Technology to Create Sustainable Value



Execution Power Provided by Bayer's Large-Pharma Infrastructure

Collaboration and Services Agreement

Announced January 7, 2021

- Expertise and Infrastructure

Adding **operational knowledge**, broad **international reach** and regional access to support global supply of CureVac's CVnCoV


- Product Development Support

Adding muscle in areas such as **clinical operations, regulatory affairs, pharmacovigilance, and supply chain performance**

- Key Territory Operations

Adding country support for **EU member states and beyond**

CureVac to be Market Authorization Holder, option for Bayer in other markets outside the EU



World-Leading Vaccine Expertise with GSK for next generation mRNA COVID-19 vaccines



Co-Development Partnership

Announced July 20, 2020, extended on January 3, 2021

■ Vaccine Development Expertise

Joint development of **2nd generation mRNA** vaccines including monovalent and multivalent approaches to address emerging variants in one vaccine

Joint efforts to address new and future variants to **stay one step ahead of the pandemic** with resources to research, development and manufacturing

Focus on developing **post-pandemic** vaccines

■ Commercialization Roles

GSK to be Marketing Authorization Holder with exclusive rights for development, manufacturing, and commercialization

CureVac to **retain three commercial areas:**
Germany, Austria, Switzerland



Vaccine
development
expertise



Combination
vaccines



International
reach

Research and Development Collaboration

Announced February 5, 2021

- **Scientific Variant Assessment and Selection**

Assessing novel **vaccines for SARS-CoV-2 variants** and vaccine approaches against selected mutations

Building on the VTF **leading scientific expertise**

Mitigate the effects of the **current pandemic**, help manage and prepare for **future outbreaks**

- **Clinical trial execution**

Clinical studies are **expected to be undertaken in the UK** towards securing marketing authorizations for jointly selected vaccines

- **Manufacturing and distribution**

Technology transfer by CureVac

Resulting vaccines expected to be **manufactured and distributed in the UK and its overseas and dependent territories**



Department for
Business, Energy
& Industrial Strategy



Scientific
expertise



World Class Variant
Vaccines Expert
Advisory Group



Fast-track clinical trial
execution and
regulatory oversight



Variant
Surveillance



- **Service** Agreement
- MAH:
 - **CureVac** in the EU
 - **Option for Bayer** in other geographies



- Upfront: **€75 m**
- Milestone: **€75 m**
- Development cost/profit split: **50:50**
- MAH: **GSK**



Department for
Business, Energy
& Industrial Strategy

- Each party carries **own R&D costs**
- **UK to purchase 50m doses**
- MAH: **CureVac**


Scaling-up a Broad and High-Performing Manufacturing Network

- Network of highly experienced CDMO partners for key manufacturing steps
- Flexible network expected to serve a variable demand, while mitigating supply chain risks
- Expected network annual output of up to 300m doses in 2021 and up to 1billion doses in 2022



RNA Printer™ **Fully automated, mobile** **GMP-grade manufacturing**

- Pandemic preparedness
- Customized therapeutics
- Clinical development





Three key partnerships to deliver on our COVID-19 ambitions in first and second generation vaccines



The Bayer collaboration represents a key success factor for clinical and commercial roll out and delivery of CVnCoV and derived first generation vaccine candidates



The GSK partnership is a strong value driver for our strategy to address both current and emerging COVID-19 variants through second-generation vaccines



The UK government collaboration is a central enabler for the spectrum of both, first and second generation COVID-19 vaccines as a source for highest quality scientific input



Our manufacturing capacities including the RNA Printer will continue to grow and we were able to update our 2022 capacity to 1 billion doses



**Thank you for your
interest**

CureVac
www.curevac.com